These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2618590)

  • 1. Stimulation of endogenous L-dopa biosynthesis--a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH).
    Birkmayer GJ; Birkmayer W
    Acta Neurol Scand Suppl; 1989; 126():183-7. PubMed ID: 2618590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease.
    Birkmayer W; Birkmayer GJ
    Ann Clin Lab Sci; 1989; 19(1):38-43. PubMed ID: 2644889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients.
    Birkmayer W; Birkmayer GJ; Vrecko K; Mlekusch W; Paletta B; Ott E
    J Neural Transm Park Dis Dement Sect; 1989; 1(4):297-302. PubMed ID: 2597315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.
    Kuhn W; Müller T; Winkel R; Danielczik S; Gerstner A; Häcker R; Mattern C; Przuntek H
    J Neural Transm (Vienna); 1996; 103(10):1187-93. PubMed ID: 9013405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application.
    Birkmayer JG; Vrecko C; Volc D; Birkmayer W
    Acta Neurol Scand Suppl; 1993; 146():32-5. PubMed ID: 8101414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is NADH effective in the treatment of Parkinson's disease?
    Swerdlow RH
    Drugs Aging; 1998 Oct; 13(4):263-8. PubMed ID: 9805207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extraction and Quantitation of Nicotinamide Adenine Dinucleotide Redox Cofactors.
    Lu W; Wang L; Chen L; Hui S; Rabinowitz JD
    Antioxid Redox Signal; 2018 Jan; 28(3):167-179. PubMed ID: 28497978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type.
    Birkmayer JG
    Ann Clin Lab Sci; 1996; 26(1):1-9. PubMed ID: 8834355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients.
    Birkmayer W; Birkmayer JG; Vrecko K; Paletta B
    Adv Neurol; 1990; 53():545-9. PubMed ID: 2239495
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of NAD
    Huang Q; Sun M; Li M; Zhang D; Han F; Wu JC; Fukunaga K; Chen Z; Qin ZH
    Mol Neurobiol; 2018 Jul; 55(7):6063-6075. PubMed ID: 29164394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy and tactic of modern Parkinson therapy.
    Birkmayer W; Birkmayer GJ
    Acta Neurol Scand Suppl; 1989; 126():63-6. PubMed ID: 2694735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A spontaneous mutation in the nicotinamide nucleotide transhydrogenase gene of C57BL/6J mice results in mitochondrial redox abnormalities.
    Ronchi JA; Figueira TR; Ravagnani FG; Oliveira HC; Vercesi AE; Castilho RF
    Free Radic Biol Med; 2013 Oct; 63():446-56. PubMed ID: 23747984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation by nicotinamide adenine dinucleotide of sympathetic and sensory-motor neurotransmission via P1-purinoceptors in the rat mesenteric arterial bed.
    Ralevic V
    Br J Pharmacol; 1995 Apr; 114(8):1541-8. PubMed ID: 7599921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia.
    Rainer M; Kraxberger E; Haushofer M; Mucke HA; Jellinger KA
    J Neural Transm (Vienna); 2000; 107(12):1475-81. PubMed ID: 11459000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.
    Allain H; Destée A; Petit H; Patay M; Schück S; Bentué-Ferrer D; Le Cavorzin P
    Eur Neurol; 2000; 44(1):22-30. PubMed ID: 10894991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.